Difference between revisions of "Team:SDSZ-China"

Line 276: Line 276:
 
                 <div class="col-sm-12">
 
                 <div class="col-sm-12">
 
                     <h1 id='overview'>Background</h1>
 
                     <h1 id='overview'>Background</h1>
 
+
                     <p>Bear bile, one of the most famous animal drugs in Traditional Chinese Medicine (TCM), has been recorded in ancient Chinese medicine book as a significant method to treat hepatic and biliary disorders. UDCA, the effective ingredient of bear bile.Aside from the traditional use of bear bile in Chinese medicine, UDCA(ursodeoxycholic acid), the effective ingredient of bear bile acid, has a much larger pharmaceutical application. As well as the usage of UDCA in dissolving gallstone, its efficacy in primary biliary cirrhosis and primary sclerosing cholangitis (PSC) as an adjunct to medical therapy has been well established. Newer indications include its use in the management of chronic hepatitis, cirrhosis, post liver transplant rejection, graft-versus-host disease and acute viral hepatitis, where it not only relieves symptoms of cholestasis but also arrests ongoing hepatocyte necrosis. However, the increasing demand for bear bile has caused bears to be in an endangered state: bear poaching and illegal animal trade have greatly dwindled the number of the wild Asiatic black bear. Apart from that, bear bile farming industry in Asia extracts bile through “milking” from the bears, which is operated through surgically implanting a permanent catheter in the animal's gallbladder to obtain the drips. It is unquestionable that the bear bile farming process will lead to both physical and psychological damage in bears. </p>
                     <p>Cataracts are the leading cause of blindness today, affecting 20 million people worldwide (World
+
                        Health Organization). Half of Americans above 80 years old are affected by cataracts (National
+
                        Eye Institute), and so are many animals! The National Eye Institute projects that in 30 years,
+
                        the number of cataract patients will increase to 50 million (National Eye Institute). </p>
+
 
                 </div>
 
                 </div>
 
             </div>
 
             </div>
 
+
<!--
 
+
 
             <div class="row">
 
             <div class="row">
 
                 <div class="col-sm-12">
 
                 <div class="col-sm-12">
Line 385: Line 380:
 
                             <figcaption class='darkblue' style="font-color:red"><b>Figure 1.5.</b> Our goal is to
 
                             <figcaption class='darkblue' style="font-color:red"><b>Figure 1.5.</b> Our goal is to
 
                                 replace surgery with noninvasive eye drops that prevent and treat cataracts.
 
                                 replace surgery with noninvasive eye drops that prevent and treat cataracts.
                            </figcaption>
 
                        </figure>
 
                    </div>
 
 
                </div> <!-- Container -->
 
            </div> <!-- Container -->
 
 
 
            <div class="row">
 
                <div class="col-sm-12">
 
                    <h2 id='solution'>What is our Solution?</h2>
 
                    <div class="row">
 
                        <div class="col-sm-12">
 
                            <p>
 
                                Our goal is to develop noninvasive, easy-to-use, and affordable eyedrops to prevent and
 
                                treat cataracts (Figure 1.5).
 
                            </p>
 
                        </div>
 
                    </div>
 
                    <div class="row">
 
 
                        <div class="col-sm-12">
 
                            <h3 id="prevention">Prevention</h3>
 
                            <p>
 
                                When GSH is present, H₂O₂ can oxidize GSH instead of crystallin proteins. When GSH
 
                                becomes oxidized, a disulfide bond forms between two GSH molecules, which become
 
                                oxidized glutathione (GSSG). Through literature research, we found an enzyme that
 
                                recycles GSSG back into GSH. This enzyme is called glutathione reductase (GSR) (Ganea &
 
                                Harding, 2006). As seen in Figure 1.6, GSR (green) recycles GSSG back into GSH, so that
 
                                crystallin proteins remain protected. Even though GSR exists in the lens, its levels
 
                                decrease with age, which leads to the development of cataracts (Michael & Bron, 2011).
 
                                <b>Our goal is to independently produce and deliver GSR to the lens, so that cataract
 
                                    formation is prevented. </b>
 
 
                            </p>
 
                        </div>
 
 
                    </div>
 
                    <div class="row">
 
 
 
                        <div class="col-sm-4"><img
 
                                src="https://static.igem.org/mediawiki/2016/b/b0/T--TAS_Taipei--ClearAnimation1.gif"></div>
 
 
                        <div class="col-sm-4"><img
 
                                src="https://static.igem.org/mediawiki/2016/3/30/T--TAS_Taipei--BlurredAnimation1.gif"></div>
 
 
                        <div class="col-sm-4"><img
 
                                src="https://static.igem.org/mediawiki/2016/7/7f/T--TAS_Taipei--AnimatinoLegend.gif"></div>
 
 
                        <figure class="col-sm-12">
 
                            <figcaption class='darkblue'><b>Figure 1.6 </b>In a normal lens (left), GSR (enzyme, in
 
                                green) converts GSSG into GSH. H₂O₂ oxidizes GSH instead of crystallin proteins, so that
 
                                crystallin proteins remain protected, and the lens remains clear. In a cataractous lens
 
                                (right), GSR levels are low so GSH cannot be remade. Since GSH is not present to protect
 
                                proteins against H₂O₂, cataracts begin to develop.
 
                            </figcaption>
 
                        </figure>
 
 
 
                    </div>
 
                    <br><br>
 
 
                    <div class="row">
 
 
                        <div class="col-sm-8">
 
                            <h3 id="treatment">Treatment</h3>
 
                            <p>
 
                                We also found a molecule that can restore solubility of protein clumps and lens
 
                                transparency. It is called 25-hydroxycholesterol (25HC) (Makley et al., 2015). 25HC can
 
                                be produced from cholesterol by the enzyme cholesterol 25-hydroxylase (CH25H) (Figure
 
                                1.7). Our goal is to independently produce and deliver CH25H to the lens, so that
 
                                cataracts can be treated.
 
 
                            </p>
 
                        </div>
 
                        <figure class="col-sm-4">
 
                            <img src="https://static.igem.org/mediawiki/2016/7/7c/T--TAS_Taipei--CH25HRxnDescription.png">
 
                            <figcaption class='darkblue'><b>Figure 1.7. </b>CH25H (enzyme) converts cholesterol to 25HC,
 
                                which can reverse protein clumps.
 
 
                             </figcaption>
 
                             </figcaption>
 
                         </figure>
 
                         </figure>
Line 470: Line 385:
  
 
                 </div>
 
                 </div>
 +
            </div>
  
 
            </div> <!-- Container -->
 
 
             <br><br>
 
             <br><br>
 
             <div class="row">
 
             <div class="row">
Line 514: Line 428:
 
                 </div>
 
                 </div>
 
             </div>
 
             </div>
 
+
-->
  
 
         </div>
 
         </div>

Revision as of 09:55, 1 November 2017


Background - TAS Taipei iGEM Wiki

Background

Bear bile, one of the most famous animal drugs in Traditional Chinese Medicine (TCM), has been recorded in ancient Chinese medicine book as a significant method to treat hepatic and biliary disorders. UDCA, the effective ingredient of bear bile.Aside from the traditional use of bear bile in Chinese medicine, UDCA(ursodeoxycholic acid), the effective ingredient of bear bile acid, has a much larger pharmaceutical application. As well as the usage of UDCA in dissolving gallstone, its efficacy in primary biliary cirrhosis and primary sclerosing cholangitis (PSC) as an adjunct to medical therapy has been well established. Newer indications include its use in the management of chronic hepatitis, cirrhosis, post liver transplant rejection, graft-versus-host disease and acute viral hepatitis, where it not only relieves symptoms of cholestasis but also arrests ongoing hepatocyte necrosis. However, the increasing demand for bear bile has caused bears to be in an endangered state: bear poaching and illegal animal trade have greatly dwindled the number of the wild Asiatic black bear. Apart from that, bear bile farming industry in Asia extracts bile through “milking” from the bears, which is operated through surgically implanting a permanent catheter in the animal's gallbladder to obtain the drips. It is unquestionable that the bear bile farming process will lead to both physical and psychological damage in bears.